SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-031087
Filing Date
2024-06-24
Accepted
2024-06-24 16:01:15
Documents
14
Period of Report
2024-06-21
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20031581_8k.htm   iXBRL 8-K 59457
2 EXHIBIT 10.1 ef20031581_ex10-1.htm EX-10.1 106631
  Complete submission text file 0001140361-24-031087.txt   329937

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bbio-20240621.xsd EX-101.SCH 3868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20240621_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20240621_pre.xml EX-101.PRE 16046
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20031581_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 241064197
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)